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Abstract: Early initiation of antiretroviral treatment (ART) reduces
HIV transmission and has health benefits. HIV drug resistance can
limit treatment options and compromise use of ART for HIV
prevention. We evaluated drug resistance in 85 participants in the
HIV Prevention Trials Network 052 trial who started ART at CD4
counts of 350–550 cells per cubic millimeter and failed ART by May
2011; 8.2% had baseline resistance and 35.3% had resistance at ART
failure. High baseline viral load and less education were associated
with emergence of resistance at ART failure. Resistance at ART
failure was observed in 7 of 8 (87.5%) participants who started ART
at lower CD4 cell counts.
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INTRODUCTION
The multinational HIV Prevention Trials Network
(HPTN) 052 trial showed that early initiation of antiretroviral
treatment (ART) significantly reduces sexual HIV transmission
in serodiscordant couples.1,2 Early ART initiation has also been
shown to have health benefits for the HIV-infected individual
receiving treatment, including lower rates of severe illness3–5
and increased survival.6 In the United States, ART has been
recommended for all HIV-infected individuals regardless of
CD4 cell count since 2012.7,8 The World Health Organization
guidelines were recently changed to recommend ART for all
HIV-infected individuals, regardless of CD4 cell count.9
Use of ART for HIV treatment and prevention can be
compromised by HIV drug resistance, especially in resource-
limited settings where resistance testing is not routinely
performed as part of clinical management. There is relatively
little information available about emergence of HIV drug
resistance in individuals who initiate ART at higher CD4 cell
counts. Observational studies in the United Kingdom and North
America have reported a lower prevalence of treatment-
emergent HIV drug resistance among patients who start ART
early.10–12 However, little is known about the factors associated
with drug resistance in HIV-infected individuals who initiate
ART at higher CD4 cell counts or in settings where ART is
used for HIV prevention. In this study, we analyzed HIV drug
resistance among HIV-infected individuals who failed ART in
the HPTN 052 trial before the interim study report was released.
METHODS
Study Cohort
HPTN 052 (NCT00074581) was a phase 3, random-
ized, controlled clinical trial that enrolled HIV serodiscordant
couples in Africa, Asia, and the Americas.1–3 HIV-infected
(index) participants had CD4 cell counts of 350–550 cells per
cubic millimeter at enrollment. In the early ART arm, index
participants initiated ART immediately after enrollment. In
the delayed ART arm, index participants initiated ART when
their CD4 cell count was,250 cells per cubic millimeter on 2
consecutive study visits or when they developed an AIDS-
defining illness.1 Viral load was measured quarterly.
Enrollment criteria for index participants included no
previous antiretroviral (ARV) drug use, except for short-term
regimens for prevention of mother-to-child transmission.
Participants who had a viral load #400 copies per milliliter
at enrollment were excluded from the analyses; some of those
participants were found to be on ART at the time of
enrollment but did not disclose this to study staff.13 The
most common ART regimen used was a combination of
efavirenz, lamivudine, and zidovudine.1 This report includes
analysis of data from the start of the trial (June 2007) through
May 2011 (interim report of the primary study outcome).
Laboratory Methods
HIV viral load and CD4 cell count were determined at
study sites.1 HIV genotyping was performed retrospectively
using the ViroSeq HIV-1 Genotyping System, v2.8 (Celera
Diagnostics, Alameda, CA). This testing was performed at
4 study sites (Pune and Chennai, India; Johannesburg, South
Africa; Rio de Janeiro, Brazil) and at the HPTN Laboratory
Center (Baltimore, MD, USA). Resistance results were
calculated using the Resistance Calculator program at
Frontier Science Foundation using the Stanford v6.3 algo-
rithm.14 Sequences were submitted to GenBank (accession
numbers: KT833391-KT833560, KU562071-KU562085).
HIV subtyping was performed by phylogenetic analysis.
Laboratories that performed HIV genotyping participated in
the US Division of AIDS Virology Quality Assurance
program.15 Laboratories that performed CD4 cell count
testing participated in the United Kingdom National
External Quality Assessment Service external quality
assurance program.16
Statistical Analysis
Viral suppression was defined as the first of 2
consecutive viral load measurements #400 copies per
milliliter after ART initiation. ART failure was defined as
the first of 2 consecutive viral load measurements .1000
copies per milliliter after 24 weeks on ART. HIV drug
resistance was assessed by testing samples collected at ART
initiation (baseline) and ART failure. Demographic and
clinical factors were analyzed for association using logistic
regression. The association of baseline resistance with time to
viral suppression after ART initiation was analyzed using
Cox proportional hazards model. Analyses were performed
using SAS software, v9.4 (SAS Institute, Cary, NC).
Ethical Considerations
Written informed consent was obtained from all
participants in the HPTN 052 trial. The trial was approved
by the institutional review boards/ethics committees at each
participating institution.
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RESULTS
Study Cohort
In HPTN 052, 886 index participants were randomized to
the early ART arm; 95 (10.7%) of those participants failed ART
by May 2011. Ten participants were excluded from analysis
(2 had viral loads #400 copies/mL at enrollment and 8 did not
have paired genotyping results from baseline and ART failure
visits). The remaining 85 participants had a median follow-up of
1.99 years (range: 0.74–5.65) in the period assessed. The median
baseline log10 viral load was 4.42 copies/mL (interquartile range:
3.76–4.86) and the median baseline CD4 cell count was 459.5
cells per cubic millimeter (interquartile range: 373–542.5). Most
(39/42 = 92.9%) HIV infections at the African sites were subtype
C; other infections included varied HIV subtypes with 1 to eight
infections of each subtype (Table 1). Therefore, HIV subtype
was not included in the analyses below. We did not observe an
association between region (Africa, the Americas, and Asia) and
resistance in any of the analyses described below.
In the delayed ART arm, 213 (24.0%) of 887 index
participants started ART in this study and 9 failed ART by
May 2011. Genotyping results were obtained for 7 of 9
participants at baseline and eight of those participants at ART
failure (6 had paired baseline/failure results).
HIV Drug Resistance
In the early ART arm, 7 (8.2%) of the 85 participants who
failed ART had drug resistance mutations detected at baseline
TABLE 1. Factors Associated With HIV Drug Resistance at Initiation of Antiretroviral Treatment (baseline) and at the Time of
Treatment Failure*
Variables Total
Resistance at Baseline Resistance at ART Failure New Resistance at ART Failure
N (%)
Odds Ratio
(95% CI) P N (%)
Odds Ratio




,25 12 2 (17) 6 (50) ref 5 (42) ref
25–39 57 5 (9) 20 (35) 0.54 (0.15 to 1.90) 0.34 18 (32) 0.65 (0.18 to 2.32) 0.50
$40 16 0 (0) 4 (25) 0.33 (0.07 to 1.65) 0.18 4 (25) 0.47 (0.09 to 2.34) 0.35
Sex
Male 47 3 (6) ref 17 (36) ref 17 (36) ref
Female 38 4 (11) 1.73 (0.36 to 8.23) 0.49 13 (34) 0.92 (0.37 to 2.25) 0.85 10 (26) 0.63 (0.25 to 1.61) 0.33
Baseline CD4 cell count† 84 7 (8) 0.92 (0.47 to 1.80) 0.80 30 (35) 0.70 (0.46 to 1.05) 0.09 26 (31) 0.75 (0.49 to 1.13) 0.17
Baseline log10 viral load‡ 85 7 (8) 0.65 (0.21 to 1.99) 0.45 30 (35) 2.36 (1.17 to 4.78) 0.017 27 (32) 3.02 (1.41 to 6.49) 0.0046
Region§
Americas 14 2 (14) ref 5 (36) ref 5 (36) ref
Asia 29 2 (7) 0.44 (0.06 to 3.54) 0.44 10 (34) 0.95 (0.25 to 3.60) 0.94 10 (34) 0.95 (0.25 to 3.60) 0.94
Africa 42 3 (7) 0.46 (0.07 to 3.09) 0.43 15 (36) 1.00 (0.28 to 3.53) 1.00 12 (29) 0.72 (0.20 to 2.59) 0.62
Regimenk
EFV/3TC/ZDV 66 6 (9) 1.80 (0.20 to 15.9) 0.60 26 (39) 2.44 (0.73 to 8.16) 0.15 24 (36) 3.05 (0.81 to 11.5) 0.10
Other 19 1 (5) ref 4 (21) ref 3 (16) ref
Education
None 16 2 (13) 10 (63) ref 9 (56) ref
Primary or secondary
schooling
65 5 (8) 19 (29) 0.25 (0.08 to 0.78) 0.017 17 (26) 0.28 (0.09 to 0.85) 0.026
Postsecondary schooling 4 0 (0) 1 (25) 0.20 (0.02 to 2.39) 0.20 1 (25) 0.26 (0.02 to 3.06) 0.28
Marital status
Married 81 6 (7) ref 28 (35) ref 25 (31) ref
Not married 4 1 (25) 4.17 (0.37 to 46.4) 0.25 2 (50) 1.89 (0.25 to 14.2) 0.53 2 (50) 2.24 (0.30 to 16.8) 0.43
No. sex partners
0–1 82 7 (9) 29 (35) ref 26 (32) ref
.1 3 0 (0) 1 (33) 0.91 (0.08 to 10.5) 0.94 1 (33) 1.08 (0.09 to 12.4) 0.95
Baseline resistance
Yes 7 7 (100) 4 (57) 3.19 (0.66 to 15.4) 0.15
No 78 23 (29) 23 (29) ref
P , 0.05 are bolded. Regression models could not be generated if any cell was 0 for the categorical variable.
*The analyses included the 85 HIV-infected index participants in the early ART arm of HPTN who failed ART (see text).
†Assessed as increments of 100 CD4-positive cells per cubic millimeter.
‡Assessed as increments of log10 viral load.
§The 85 participants had the following HIV subtypes: 69 (81.2%) subtype C (Malawi [N = 29], India [N = 28], Zimbabwe [N = 7], South Africa [N = 3], and Brazil [N = 2]),
8 subtype B (Brazil), 3 subtype F1 (Brazil), 1 subtype A2 (Kenya), 2 A1 (Kenya), 1 CRF1_AE (Thailand), and 1 CRF12_BF (Brazil).
║Most participants who started ART on the EFV/3TC/ZDV regimen (with the exception of pregnant women) received a fixed-dose formulation of these drugs.
3TC, lamivudine; EFV, efavirenz; ref, reference group; ZDV, zidovudine.
(including 4 women, one of whom reported previous use of
ARV drugs during pregnancy, Fig. 1). Three had nonnucleoside
reverse transcriptase inhibitor (NNRTI) resistance only, 1 had
nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)
resistance only, and 3 had both NNRTI and NRTI resistances.
Thirty (35.3%) of the 85 participants had drug resistance
mutations detected at ART failure; 19 had NNRTI resistance
only, 3 had NRTI resistance only, and 8 had both NNRTI and
NRTI resistances (Fig. 1). Twenty-seven (90.0%) of the 30
participants had resistance mutations detected at failure that
were not present at baseline. Twenty-three had new NNRTI
resistance; all had new resistance to efavirenz, and most had
cross-resistance to other NNRTIs. Eight had new NRTI
resistance; all had new resistance to lamivudine and emtricita-
bine; 1 also had new resistance to abacavir and didanosine.
Protease inhibitor resistance was not observed in any samples.
In the delayed ART arm, baseline resistance was detected
in 2 (28.6%) of 7 participants with genotyping results. At ART
failure, 7 (87.5%) of 8 participants who had genotyping results
had resistance, including all 6 participants with paired baseline/
failure results. Both of the participants who had baseline
resistance acquired new resistance at failure. The frequency of
resistance at ART failure was significantly higher in the
delayed ART arm compared with the early ART arm (7/8
[87.5%] vs. 30/85 [35.2%], P = 0.006, Fisher exact test).
Factors Associated With HIV Drug Resistance
Because only 9 participants in the delayed ART failed
ART by the May 2011 arm, factors associated with HIV drug
resistance were assessed in the early ART arm only. None of
the clinical or demographic factors analyzed were associated
with baseline drug resistance among those who failed ART
(Table 1). A higher baseline viral load was associated with
resistance at ART failure and with new resistance at ART
failure. Having primary or secondary schooling (compared to
no education/schooling) was associated with a lower fre-
quency of resistance at ART failure and new resistance at
ART failure. Baseline drug resistance was not associated with
time to viral suppression after ART initiation among the 85
participants who failed ART; 50 (58.8%) of the 85 partic-
ipants never achieved viral suppression before meeting the
criteria for ART failure. There was no difference (P = 0.2, x2
test) in the frequency of new resistance at ART failure among
those who never achieved viral suppression (15/50 = 30.0%),
those who achieved viral suppression and remained virally
suppressed before ART failure (10/28 = 35.7%), and those
who achieved viral suppression but had intermittent viremia
before ART failure (2/7 = 28.6%).
DISCUSSION
HIV drug resistance may compromise the use of ART for
HIV treatment and prevention. ART is now recommended for all
HIV-infected individuals, regardless of CD4 cell count.7–9,17,18
However, few studies have evaluated HIV drug resistance when
ART is initiated at higher CD4 cell counts. Among participants
who failed ART in the early ART arm of HPTN 052 (data
through May 2011), 8.2% had resistance at the time of ART
initiation. This is similar to the frequency of baseline resistance
among participants who failed ART in the ACTG 5175 study
(Prospective Evaluation of Antiretrovirals in Resource-Limited
Settings [PEARLS]), which enrolled participants at many of the
same study sites as HPTN 052. In PEARLS, ART was initiated
at lower CD4 cell counts (,300 cells/mm3); the frequency of
baseline resistance in PEARLS was 9.4% among those who
FIGURE 1. Proportion of participants with HIV
drug resistance at baseline and at treatment
failure. The figure shows the frequency of HIV
drug resistance among participants in the early
ART arm of HPTN 052 who failed ART (N = 85
with paired baseline/failure results). Seven
(8.2%) participants had resistance at baseline.
The most common NNRTI and NRTI mutations
were Y181C and M184V, which were each
detected in 3 of the 7 cases. All the mutations
detected at baseline, with the exception of one
Y181C mutation, were also present in the cor-
responding failure samples. Thirty (35.3%) had
resistance at ART failure. The most common
NNRTI mutation was K103N, which was de-
tected in 20 (66.7%) of the 30 cases. The most
common NRTI mutation was M184V, which
was detected in 11 (36.7%) of the 30 cases.
Twenty-seven (90.0%) of those 30 participants
had one or more resistance mutations detected
at failure that was not present at the time of ART initiation (K103N [n = 18], M184V [n = 8], V106M [n = 4], V108I [n = 2], K238T
[n = 2], G190A [n = 1], and K101E [n = 1]). Twenty-three (85.2%) had new resistance to efavirenz, and most had cross-resistance
to other NNRTIs (nevirapine [N = 21], rilpivirine [N = 2], and etravirine [N = 1]). Eight (29.6%) had new NRTI resistance; all had
new resistance to lamivudine and emtricitabine; 1 also had new resistance to abacavir and didanosine because of the acquisition
of M184V in addition to the baseline mutations M41L and T215E. Protease inhibitor resistance was not observed in any samples.
Among the 78 (91.8%) participants who did not have baseline resistance, 23 (27.1%) had resistance at failure (not shown).
viral load monitoring, and prompt cessation of ART at ART
failure (with a switch to a new regimen when feasible and
appropriate) are likely to maximize the success of ART and
reduce the risk of HIV drug resistance in both treatment
and prevention settings.
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failed ART and 4.3% among those in a case–control group of 
those who did not fail ART.19
In HPTN 052, the frequency of resistance at ART 
failure was significantly lower in the early ART arm than in 
the delayed ART arm (35.3% vs. 87.5%, P = 0.006). It is 
important to note, however, that very few participants in the 
delayed ART arm failed ART by May 2011. In other studies 
where ART was initiated at lower CD4 cell counts, the 
frequency of resistance at ART failure was also higher than 
that observed in the early ART arm of HPTN 052 (70%–84%
in 2 clinical cohort studies in sub-Sarahan Africa20,21; 50% in 
a randomized controlled clinical trial in the United States22). 
Many factors may have contributed to the lower rate of HIV 
drug resistance observed in the early ART arm of HPTN 052. 
In HPTN 052, participants in both study arms received 
adherence counseling and had quarterly viral load monitoring. 
Participants in the early ART arm may have been more likely 
to adhere to ART because they were taking ART primarily as 
an intervention to prevent partner infection, rather than for 
their own health.
Among participants in the early ART arm who failed 
ART, there was a strong association between higher baseline 
viral load and emergence of resistance at ART failure. This is 
consistent with results from an observational cohort study in 
Canada that reported an association of high baseline viral load 
and resistance at ART failure when ART was initiated at 
lower CD4 cell counts (median: 280 cells/mm3).23 Persons 
with higher baseline viral loads may have more diverse viral 
populations with a higher frequency of low-level drug-
resistant variants or may have higher viral replication rates; 
these factors could favor emergence of resistant variants at 
ART failure. Of note, relatively few of the participants 
analyzed in this study had baseline resistance; therefore, 
further studies are needed to evaluate the clinical relevance of 
this association. We also found an association between 
educational level and resistance at ART failure. Further 
studies are needed to determine whether this reflects an 
association between educational level and ART adherence.
More than half of the participants who failed ART in 
this study never achieved viral suppression. There was no 
difference in resistance at ART failure among those who 
never achieved viral suppression, those who achieved viral 
suppression and remained suppressed until ART failure, and 
those who achieved viral suppression but had intermittent 
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